Why Trump’s revenue-raising patent plan is riddled with problems

A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AI is transforming top 100 innovators, shows index

23 January 2026 Just one pharma company is recognised in a report that lists the most world's most inventive countries and companies.

Americas

Novartis win blocks generics relitigating $7.8bn heart drug patent

22 January 2026 A district court judge shuts down a Novartis rival from reopening validity and infringement arguments over an Entresto patent.

Americas

Leading the arena: WIPR identifies the top US trade secrets specialists of 2025

22 January 2026 New rankings from LSIPR’s sister title spotlight the firms and lawyers that are most successfully navigating the volatile world of trade secrets, from ‘prompt injections’ to billion-dollar retrials.

More features

AI is transforming top 100 innovators, shows index

Novartis win blocks generics relitigating $7.8bn heart drug patent

Leading the arena: WIPR identifies the top US trade secrets specialists of 2025

Rooted rights: Lessons from plant patent infringement and invalidity cases

Cadwalader global head among trio moving to Orrick

Skinny labels, big stakes: SCOTUS lines up the case of the year

Chinese biotech strikes billion dollar deal in nextgen cancer race

$5.4bn medtech leader fails to bury a rival's patent

Why Trump’s revenue-raising patent plan is riddled with problems

More on this story

Editor's picks

Editor's picks

More features